Astellas and FribroGen present positive data for new oral therapy in CKD
Japan’s Astellas Pharma (TSE: 4503) and USA-based FibroGen (Nasdaq: FGEN) have presented Phase III data from two studies looking at roxadustat in the treatment of anemia associated with chronic kidney disease (CKD).
The positive data was presented at the American Society of Nephrology Kidney Week 2018 in San Diego, California.
The 1517-CL-0302 study, which evaluated the efficacy and safety of roxadustat in Japanese CKD patients on peritoneal dialysis (PD), found the drug was well tolerated and achieved and maintained hemoglobin (Hb) levels within the target range.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze